urapidil has been researched along with Cardiac Failure in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients (>60 y) with hypertension and heart failure were randomly assigned to receive intravenous urapidil (n=89) or nitroglycerin (n=91) for 7 days." | 9.24 | Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial. ( Chen, XM; Fu, Y; Guo, JC; He, JY; Hua, Q; Li, J; Qin, J; Qin, S; Wang, Z; Yang, W; Zhan, H; Zhou, YJ, 2017) |
| "To evaluate the effects of a combined therapy on quality of life, exercise tolerance, and hemodynamic parameters, patients with severe heart failure (New York Heart Association classes III and IV, ejection fraction below 35%) who were on ACE inhibitor therapy were randomly assigned to additional double-blind treatment with urapidil (60-120 mg/d) or placebo for 12 weeks." | 9.08 | Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study. ( Dorszewski, A; Dorsźewski, B; Figulla, HR; Göhmann, E; Kreuzer, H; Werner, GS, 1997) |
| "PubMed, EMBASE, the Cochrane Library and China National Knowledge Infrastructure were searched for randomized studies that compared urapidil treatment with nitroglycerin treatment for hypertensive patients with acute heart failure." | 9.01 | Urapidil, compared to nitroglycerin, has better clinical safety in the treatment of hypertensive patients with acute heart failure: a meta-analysis. ( Ding, H; Feng, S; Li, Y; Ning, G; Peng, P; Shi, H; Shi, J; Xing, C; Zheng, P, 2019) |
| "Previous clinical studies have reported that urapidil can effectively treat patients with senile hypertension (SH) and acute heart failure (AHF)." | 7.91 | Efficacy of urapidil for the treatment of patients with senile hypertension and acute heart failure. ( Ding, GR; Feng, JF; Ni, JM; Xie, YZ; Zhang, SJ, 2019) |
| "The Authors report their experience with a new vasodilator drug (Urapidil) employed in the management of serious cardiac failure, in a patient who previously didn't respond in a satisfactory manner to a therapy with Dopamine alone." | 7.68 | [Urapidil and dopamine in severe heart failure. A clinical case]. ( Balla, E; Bono, D; Fenoglio, L; Ravera, E, 1992) |
| "The acute haemodynamic and myocardial metabolic effects of intravenous urapidil were evaluated in 12 patients with severe congestive heart failure due to coronary heart disease." | 7.67 | Acute haemodynamic and myocardial metabolic effects of intravenous urapidil in severe heart failure. ( Chan, KH; Chow, JS; Pan, HY; Wang, RY; Wong, RP, 1984) |
| "Urapidil is a therapeutic option for the multifactor heart failure patients complicated with hypertension and DM." | 6.80 | A multicenter, randomized, trial comparing urapidil and nitroglycerin in multifactor heart failure in the elderly. ( Chen, XM; Fu, Y; Guo, JC; Hua, Q; Qin, J; Qin, S; Yang, W; Zhou, YJ, 2015) |
| "Patients (>60 y) with hypertension and heart failure were randomly assigned to receive intravenous urapidil (n=89) or nitroglycerin (n=91) for 7 days." | 5.24 | Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial. ( Chen, XM; Fu, Y; Guo, JC; He, JY; Hua, Q; Li, J; Qin, J; Qin, S; Wang, Z; Yang, W; Zhan, H; Zhou, YJ, 2017) |
| "To evaluate the effects of a combined therapy on quality of life, exercise tolerance, and hemodynamic parameters, patients with severe heart failure (New York Heart Association classes III and IV, ejection fraction below 35%) who were on ACE inhibitor therapy were randomly assigned to additional double-blind treatment with urapidil (60-120 mg/d) or placebo for 12 weeks." | 5.08 | Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study. ( Dorszewski, A; Dorsźewski, B; Figulla, HR; Göhmann, E; Kreuzer, H; Werner, GS, 1997) |
| "PubMed, EMBASE, the Cochrane Library and China National Knowledge Infrastructure were searched for randomized studies that compared urapidil treatment with nitroglycerin treatment for hypertensive patients with acute heart failure." | 5.01 | Urapidil, compared to nitroglycerin, has better clinical safety in the treatment of hypertensive patients with acute heart failure: a meta-analysis. ( Ding, H; Feng, S; Li, Y; Ning, G; Peng, P; Shi, H; Shi, J; Xing, C; Zheng, P, 2019) |
| "Previous clinical studies have reported that urapidil can effectively treat patients with senile hypertension (SH) and acute heart failure (AHF)." | 3.91 | Efficacy of urapidil for the treatment of patients with senile hypertension and acute heart failure. ( Ding, GR; Feng, JF; Ni, JM; Xie, YZ; Zhang, SJ, 2019) |
| "The Authors report their experience with a new vasodilator drug (Urapidil) employed in the management of serious cardiac failure, in a patient who previously didn't respond in a satisfactory manner to a therapy with Dopamine alone." | 3.68 | [Urapidil and dopamine in severe heart failure. A clinical case]. ( Balla, E; Bono, D; Fenoglio, L; Ravera, E, 1992) |
| "The acute haemodynamic and myocardial metabolic effects of intravenous urapidil were evaluated in 12 patients with severe congestive heart failure due to coronary heart disease." | 3.67 | Acute haemodynamic and myocardial metabolic effects of intravenous urapidil in severe heart failure. ( Chan, KH; Chow, JS; Pan, HY; Wang, RY; Wong, RP, 1984) |
| "Urapidil is a therapeutic option for the multifactor heart failure patients complicated with hypertension and DM." | 2.80 | A multicenter, randomized, trial comparing urapidil and nitroglycerin in multifactor heart failure in the elderly. ( Chen, XM; Fu, Y; Guo, JC; Hua, Q; Qin, J; Qin, S; Yang, W; Zhou, YJ, 2015) |
| "Ten normotensive patients with severe congestive heart failure were given Urapidil 25 mg i." | 1.27 | Acute haemodynamic effects of urapidil in patients with chronic left ventricular failure. ( Neuhaus, KL; Tebbe, U; Wurst, W, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (25.00) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, YZ | 1 |
| Ni, JM | 1 |
| Zhang, SJ | 1 |
| Ding, GR | 1 |
| Feng, JF | 1 |
| Shi, J | 1 |
| Li, Y | 1 |
| Xing, C | 1 |
| Peng, P | 1 |
| Shi, H | 1 |
| Ding, H | 1 |
| Zheng, P | 1 |
| Ning, G | 1 |
| Feng, S | 1 |
| Vertkin, AL | 1 |
| Topolianskiĭ, AV | 1 |
| Abdullaeva, AU | 1 |
| Alekseev, MA | 1 |
| Shakhmanaev, KhA | 1 |
| Yang, W | 2 |
| Zhou, YJ | 2 |
| Fu, Y | 2 |
| Qin, J | 2 |
| Qin, S | 2 |
| Chen, XM | 2 |
| Guo, JC | 2 |
| Hua, Q | 2 |
| Wang, Z | 1 |
| Zhan, H | 1 |
| Li, J | 1 |
| He, JY | 1 |
| Wang, RY | 1 |
| Chow, JS | 1 |
| Chan, KH | 1 |
| Pan, HY | 1 |
| Wong, RP | 1 |
| Dorszewski, A | 1 |
| Göhmann, E | 1 |
| Dorsźewski, B | 1 |
| Werner, GS | 1 |
| Kreuzer, H | 1 |
| Figulla, HR | 1 |
| Stangl, K | 1 |
| Dschietzig, T | 1 |
| Richter, C | 1 |
| Laule, M | 1 |
| Stangl, V | 1 |
| Tanis, E | 1 |
| Baumann, G | 1 |
| Felix, SB | 1 |
| Balla, E | 1 |
| Fenoglio, L | 1 |
| Ravera, E | 1 |
| Bono, D | 1 |
| Adnot, S | 2 |
| Radermacher, P | 2 |
| Andrivet, P | 2 |
| Dubois-Rande, JL | 2 |
| Dupeyrat, A | 2 |
| Lemaire, F | 2 |
| Drobinski, G | 1 |
| Montalescot, G | 1 |
| Fossier, JM | 1 |
| Grosgogeat, Y | 1 |
| M'Buyamba-Kabangu, JR | 1 |
| Bielen, E | 2 |
| Staessen, J | 2 |
| Fagard, R | 2 |
| Lijnen, P | 2 |
| Van Hoof, R | 2 |
| Amery, A | 2 |
| Messerli, FH | 1 |
| Tebbe, U | 1 |
| Wurst, W | 1 |
| Neuhaus, KL | 1 |
4 reviews available for urapidil and Cardiac Failure
| Article | Year |
|---|---|
Urapidil, compared to nitroglycerin, has better clinical safety in the treatment of hypertensive patients with acute heart failure: a meta-analysis.
Topics: Acute Disease; Heart Failure; Humans; Hypertension; Nitroglycerin; Piperazines; Randomized Controlle | 2019 |
[Hypertensive crisis: pathogenesis, clinic, treatment].
Topics: Algorithms; Antihypertensive Agents; Aortic Aneurysm; Aortic Dissection; Blood Pressure; Disease Man | 2013 |
Urapidil-induced hemodynamic changes in humans.
Topics: Acute Disease; Antihypertensive Agents; Heart Failure; Hemodynamics; Humans; Hypertension; Hypertens | 1989 |
Haemodynamic effects of urapidil in arterial hypertension and congestive heart failure.
Topics: Antihypertensive Agents; Heart Failure; Hemodynamics; Humans; Hypertension; Piperazines | 1988 |
4 trials available for urapidil and Cardiac Failure
| Article | Year |
|---|---|
A multicenter, randomized, trial comparing urapidil and nitroglycerin in multifactor heart failure in the elderly.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Echocardiography; Heart Failure; Humans; Kidney Funct | 2015 |
Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial.
Topics: Acute Disease; Aged; Antihypertensive Agents; Blood Pressure; Cause of Death; Female; Heart Failure; | 2017 |
Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disease; Double-Blind Meth | 1997 |
Effects of sodium-nitroprusside and urapidil on gas exchange and ventilation-perfusion relationships in patients with congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Nitrop | 1991 |
8 other studies available for urapidil and Cardiac Failure
| Article | Year |
|---|---|
Efficacy of urapidil for the treatment of patients with senile hypertension and acute heart failure.
Topics: Acute Disease; Antihypertensive Agents; Heart Failure; Humans; Hypertension; Piperazines; Randomized | 2019 |
Acute haemodynamic and myocardial metabolic effects of intravenous urapidil in severe heart failure.
Topics: Aged; Antihypertensive Agents; Cardiac Output; Coronary Circulation; Electrocardiography; Energy Met | 1984 |
Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy.
Topics: Aged; Coronary Circulation; Endothelin-1; Endothelins; Female; Heart Failure; Hemodynamics; Humans; | 2000 |
[Urapidil and dopamine in severe heart failure. A clinical case].
Topics: Aged; Dopamine; Female; Heart Failure; Humans; Piperazines; Vasodilator Agents | 1992 |
Haemodynamic effects of intravenous urapidil in patients with advanced left ventricular failure.
Topics: Antihypertensive Agents; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Injections, Int | 1990 |
Effects of sodium nitroprusside and urapidil on gas exchange and ventilation: perfusion ratios in patients with congestive heart failure.
Topics: Antihypertensive Agents; Heart Failure; Hemodynamics; Humans; Nitroprusside; Piperazines; Pulmonary | 1990 |
[Hemodynamic effects of urapidil in men].
Topics: Antihypertensive Agents; Heart Failure; Hemodynamics; Humans; Hypertension; Hypertension, Pulmonary; | 1990 |
Acute haemodynamic effects of urapidil in patients with chronic left ventricular failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Heart Failure; Heart Rate; Hemodynamics; Humans; Kineti | 1988 |